AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30001982 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest (DNG) + 3,3'-diindolylmethane (DIM)
Number of subjects: 8
Study 30001982 — intervention group
Group type: COMPARATOR
Intervention: Dienogest (DNG)
Number of subjects: 8
Study 26845525 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental problem-solving skills training (PSST)
Number of subjects: 61
Study 26845525 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 61
Study 24682421 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofarabine 5×10 mg/m²/day
Number of subjects: 25
Study 24682421 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofarabine 15 mg/m²/day
Number of subjects: 25
Study 24682421 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofarabine 10 mg/m²/day
Number of subjects: 25
Study 24682421 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofarabine combined with cytosine arabinoside and idarubicin
Number of subjects: 25
Study 24682421 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofarabine (various doses)
Number of subjects: 25
Study 22437295 — intervention group
Group type: EXPERIMENTAL
Intervention: FJ injections (FJI)
Number of subjects: 100
Study 22437295 — intervention group
Group type: EXPERIMENTAL
Intervention: FJ radiofrequency denervation (FJRF)
Number of subjects: 100
Study 19491895 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX (capecitabine plus oxaliplatin) as first-line chemotherapy
Number of subjects: 2
Study 19491895 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX (capecitabine plus oxaliplatin) as second-line chemotherapy
Number of subjects: 2
Study 19491895 — intervention group
Group type: COMPARATOR
Intervention: XELOX (capecitabine plus oxaliplatin)
Number of subjects: 2
Study 19491895 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX4 (5-fluorouracil/folinic acid and oxaliplatin)
Number of subjects: 2
Study 17453864 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone patch (300 mug/24 h)
Number of subjects: 99
Study 17453864 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 99
Study 17453864 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 99
Study 16467024 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% TCA
Number of subjects: 51
Study 16467024 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% TCA
Number of subjects: 51
Study 16467024 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% TCA
Number of subjects: 51
Study 16467024 — intervention group
Group type: EXPERIMENTAL
Intervention: All strengths of TCA
Number of subjects: 51
Study 14998224 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapeutic management of arrhythmias
Number of subjects: 0
Study 10779453 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-radiation therapy with 90-yttrium, 20.6 Gy dose at 1.0 mm from the balloon surface
Number of subjects: 50
Study 10779453 — intervention group
Group type: COMPARATOR
Intervention: placebo group of gamma-WRIST
Number of subjects: 50
Study 8904618 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 50 mg
Number of subjects: 8
Study 8904618 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 100 mg
Number of subjects: 8
Study 8904618 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 200 mg
Number of subjects: 8
Study 8904618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1812307 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice bag
Number of subjects: 40
Study 1812307 — intervention group
Group type: COMPARATOR
Intervention: Heat lamp
Number of subjects: 40
Study 6195239 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-used haemodialysers cleaned with sodium hypochlorite and benzoic acid
Number of subjects: 206
Study 6195239 — intervention group
Group type: COMPARATOR
Intervention: New haemodialysers
Number of subjects: 206
Study 30010509 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intensity and dose exercise programs (5 days/week for four weeks)
Number of subjects: 75
Study 30010509 — intervention group
Group type: COMPARATOR
Intervention: Usual inpatient physical therapy care
Number of subjects: 75
Study 30010509 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intensity and dose exercise programs
Number of subjects: 75
Study 28005247 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose capecitabine plus docetaxel (capecitabine 825 mg/m2 twice daily, days 1-14; docetaxel 60 mg/m2, day 1 every 3 weeks)
Number of subjects: 162
Study 28005247 — intervention group
Group type: COMPARATOR
Intervention: Single-agent docetaxel (70 mg/m2, day 1 every 3 weeks)
Number of subjects: 162
Study 28005247 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose capecitabine plus docetaxel
Number of subjects: 162
Study 28005247 — intervention group
Group type: COMPARATOR
Intervention: Single-agent docetaxel
Number of subjects: 162
Study 26227087 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC fenofibrate/simvastatin 145/20 mg or 145/40 mg
Number of subjects: 0
Study 26227087 — intervention group
Group type: COMPARATOR
Intervention: FDC fenofibrate/simvastatin
Number of subjects: 0
Study 22345693 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 600
Study 21903052 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional SYNTAX score (FSS)
Number of subjects: 497
Study 21903052 — intervention group
Group type: COMPARATOR
Intervention: Classic SYNTAX score (SS)
Number of subjects: 497
Study 19657998 — intervention group
Group type: EXPERIMENTAL
Intervention: XRCC1 194Trp allele
Number of subjects: 85
Study 19657998 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 85
Study 19657998 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient group (B-cell lymphoma cases)
Number of subjects: 85
Study 19657998 — intervention group
Group type: EXPERIMENTAL
Intervention: XRCC1 194Arg/Trp genotype
Number of subjects: 85
Study 16387792 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant angina patients
Number of subjects: 12
Study 16387792 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery disease (CAD) patients
Number of subjects: 12
Study 15662751 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11065066 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of exclusive breastfeeding (categorized as never, <4 months, or ≥4 months) among children with maternal asthma
Number of subjects: 1043
Study 11065066 — intervention group
Group type: COMPARATOR
Intervention: Duration of exclusive breastfeeding (categorized as never, <4 months, or ≥4 months) among children without maternal asthma
Number of subjects: 1043
Study 9610957 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma thrombomodulin
Number of subjects: 31
Study 9610957 — intervention group
Group type: EXPERIMENTAL
Intervention: von Willebrand factor antigen
Number of subjects: 31
Study 9610957 — intervention group
Group type: EXPERIMENTAL
Intervention: tissue factor
Number of subjects: 31
Study 9610957 — intervention group
Group type: EXPERIMENTAL
Intervention: plasminogen activator inhibitor antigen
Number of subjects: 31
Study 8471513 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoralen-UVB treatment
Number of subjects: 15
Study 8471513 — intervention group
Group type: COMPARATOR
Intervention: UVB alone
Number of subjects: 15
Study 29667153 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehab + EAAs (8 g/day)
Number of subjects: 83
Study 29667153 — intervention group
Group type: COMPARATOR
Intervention: Rehab only
Number of subjects: 83
Study 29667153 — intervention group
Group type: COMPARATOR
Intervention: Rehab + placebo
Number of subjects: 83
Study 29879707 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic aerobic training 3 times a week for 4 months
Number of subjects: 30
Study 29879707 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 26747406 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected trigeminal nerve (TGN)
Number of subjects: 40
Study 26747406 — intervention group
Group type: COMPARATOR
Intervention: Unaffected trigeminal nerve (TGN)
Number of subjects: 40
Study 23748568 — intervention group
Group type: COMPARATOR
Intervention: Splinting (n=20)
Number of subjects: 56
Study 23748568 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (open reduction and stabilization with screws and wires, n=29)
Number of subjects: 56
Study 23083656 — intervention group
Group type: EXPERIMENTAL
Intervention: Saw palmetto (Serenoa repens)
Number of subjects: 339
Study 23083656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 339
Study 23083656 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cohort analysis
Number of subjects: 339
Study 23083656 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall lower urinary tract symptoms (excluding nocturia)
Number of subjects: 339
Study 20448003 — intervention group
Group type: EXPERIMENTAL
Intervention: Presenter conflict
Number of subjects: 515
Study 20448003 — intervention group
Group type: EXPERIMENTAL
Intervention: Researcher conflict
Number of subjects: 515
Study 20448003 — intervention group
Group type: COMPARATOR
Intervention: No conflict
Number of subjects: 515
Study 18029105 — intervention group
Group type: EXPERIMENTAL
Intervention: Halstead-type radical mastectomy
Number of subjects: 1665
Study 18029105 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mastectomy and radiotherapy
Number of subjects: 1665
Study 18029105 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mastectomy alone
Number of subjects: 1665
Study 15824927 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-sestamibi/18FDG DISA SPECT
Number of subjects: 58
Study 15824927 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-sestamibi/18FDG DISA SPECT (visual analysis)
Number of subjects: 58
Study 11463367 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-directed weaning
Number of subjects: 223
Study 11463367 — intervention group
Group type: COMPARATOR
Intervention: Physician-directed weaning
Number of subjects: 223
Study 9713665 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-risk Screening Instrument (HSI) developed in Phase 1
Number of subjects: 459
Study 9713665 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-risk Screening Instrument (HSI) used in Phase 2
Number of subjects: 459
Study 7527105 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril 1 mg
Number of subjects: 27
Study 7527105 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril 2 mg
Number of subjects: 27
Study 2725451 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprinters
Number of subjects: 32
Study 2725451 — intervention group
Group type: EXPERIMENTAL
Intervention: Students in PAE
Number of subjects: 32
Study 2725451 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 32
Study 2725451 — intervention group
Group type: EXPERIMENTAL
Intervention: Witnesses
Number of subjects: 32
Study 2725451 — intervention group
Group type: EXPERIMENTAL
Intervention: Divided attention condition
Number of subjects: 32
Study 2725451 — intervention group
Group type: COMPARATOR
Intervention: Sprinters vs Controls
Number of subjects: 32
Study 4599858 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin plus probenecid (3.5 g ampicillin with 1.0 g probenecid)
Number of subjects: 114
Study 4599858 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin alone (3.0 g)
Number of subjects: 114
Study 30934043 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading protocol
Number of subjects: 22
Study 30934043 — intervention group
Group type: COMPARATOR
Intervention: Delayed loading protocol
Number of subjects: 22
Study 28337821 — intervention group
Group type: EXPERIMENTAL
Intervention: Care as usual + Mindfulness-based stress reduction (CAU + MBSR)
Number of subjects: 107
Study 28337821 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 107
Study 24667900 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based hand exercises with HOA information
Number of subjects: 80
Study 24667900 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based hand exercises
Number of subjects: 80
Study 24667900 — intervention group
Group type: COMPARATOR
Intervention: Control group (information only)
Number of subjects: 80
Study 23683738 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 240
Study 23683738 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside
Number of subjects: 240
Study 23683738 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 240
Study 21485024 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) plus methotrexate (MTX)
Number of subjects: 0
Study 21485024 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus methotrexate (MTX)
Number of subjects: 0
Study 18045731 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxyaminoimidazole (CAI) 250mg daily
Number of subjects: 186
Study 18045731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 16818663 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenomethionine
Number of subjects: 29
Study 16818663 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 29
Study 16818663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 14521653 — intervention group
Group type: EXPERIMENTAL
Intervention: Long QT syndrome patients (LQTS)
Number of subjects: 10
Study 14521653 — intervention group
Group type: EXPERIMENTAL
Intervention: Short episodes of polymorphic atrial tachyarrhythmias (polyAT)
Number of subjects: 10
Study 14521653 — intervention group
Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 10
Study 14521653 — intervention group
Group type: EXPERIMENTAL
Intervention: LQTS patients with polyAT
Number of subjects: 10
Study 10984335 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation (17-19 hours without sleep)
Number of subjects: 39
Study 10984335 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation (longer periods without sleep)
Number of subjects: 39
Study 8773867 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural hydromorphone (0.6 mg)
Number of subjects: 46
Study 8773867 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine (3 mg)
Number of subjects: 46
Study 1299733 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-operative antibiotics for clean-contaminated (class B) and contaminated (class C) cases only.
Number of subjects: 400
Study 1299733 — intervention group
Group type: COMPARATOR
Intervention: Routine group received prolonged antibiotics.
Number of subjects: 400
Study 1299733 — intervention group
Group type: EXPERIMENTAL
Intervention: No antibiotics for clean cases (class A).
Number of subjects: 400
Study 6380856 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg orally 4 times a day during hospitalization + Metoprolol 15 mg intravenously 20 min after initial administration, then 50 mg 4 times a day
Number of subjects: 30
Study 6380856 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Metoprolol 15 mg intravenously 20 min after initial administration, then 50 mg 4 times a day
Number of subjects: 30
Study 6380856 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine + Metoprolol
Number of subjects: 30
Study 28921723 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cefalexin (22 mg/kg twice daily)
Number of subjects: 17
Study 28921723 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylactic cefalexin)
Number of subjects: 17
Study 27139441 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole
Number of subjects: 1760
Study 27139441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1760
Study 24716713 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) at 4 Joules
Number of subjects: 0
Study 24716713 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) at 6 Joules
Number of subjects: 0
Study 24716713 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) at 8 Joules
Number of subjects: 0
Study 24716713 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 Joules)
Number of subjects: 0
Study 24716713 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) protocol that achieved the best muscle performance in phase 1
Number of subjects: 0
Study 22976529 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish PFDI-20
Number of subjects: 78
Study 22976529 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish PFIQ-7
Number of subjects: 78
Study 22976529 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish QUID
Number of subjects: 78
Study 22976529 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish 3IQ
Number of subjects: 78
Study 22976529 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish-English agreement for individual items
Number of subjects: 78
Study 22976529 — intervention group
Group type: EXPERIMENTAL
Intervention: PFDI-20, PFIQ-7, QUID subscales scores
Number of subjects: 78
Study 20874462 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 159
Study 20874462 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 159
Study 18400585 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix 0.25 mg
Number of subjects: 251
Study 18400585 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix 0.2 mg
Number of subjects: 251
Study 18400585 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix 0.15 mg
Number of subjects: 251
Study 18400585 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (LA) 0.5 mg/day
Number of subjects: 251
Study 18400585 — intervention group
Group type: EXPERIMENTAL
Intervention: Single half-dose LA depot 1.88 mg
Number of subjects: 251
Study 16099784 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help guidebook
Number of subjects: 420
Study 16099784 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help group meeting (in addition to guidebook)
Number of subjects: 420
Study 16099784 — intervention group
Group type: COMPARATOR
Intervention: Control group (receiving neither intervention)
Number of subjects: 420
Study 12795797 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% chlorhexidine gel
Number of subjects: 43
Study 12795797 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 43
Study 10599334 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 100 mg per day
Number of subjects: 0
Study 10599334 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 300 mg per day
Number of subjects: 0
Study 10599334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8555849 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic gastrostomy
Number of subjects: 30
Study 8555849 — intervention group
Group type: COMPARATOR
Intervention: Nasogastric tube feeding
Number of subjects: 30
Study 2042567 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 90
Study 2042567 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 90
Study 2042567 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-segment deviation in ≥2 leads during chest pain (in subset of 62 patients)
Number of subjects: 90
Study 2042567 — intervention group
Group type: EXPERIMENTAL
Intervention: Total number of leads with ST changes
Number of subjects: 90
Study 6857583 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg four times per day for three days)
Number of subjects: 0
Study 6857583 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol treatment
Number of subjects: 0
Study 6857583 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin reintroduced while salbutamol continued
Number of subjects: 0
Study 3878718 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0
Study 3878718 — intervention group
Group type: COMPARATOR
Intervention: Methohexitone
Number of subjects: 0
Study 29147795 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 2 mg/kg twice daily
Number of subjects: 31
Study 29147795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 27401508 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic fentanyl pectin nasal spray (FPNS) 15%-25% of total daily opioid dose
Number of subjects: 24
Study 27401508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 24636877 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral etoposide
Number of subjects: 92
Study 24636877 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine and bleomycin
Number of subjects: 92
Study 24636877 — intervention group
Group type: COMPARATOR
Intervention: Vincristine alone
Number of subjects: 92
Study 22933567 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 10122
Study 22933567 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 10122
Study 20540767 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 5 or 10 mg daily (< 20 kg) or 10 or 20 mg daily (≥ 20 kg) for 8 weeks
Number of subjects: 109
Study 20540767 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 109
Study 18946010 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride application leading to CaF(2) formation on enamel
Number of subjects: 10
Study 15992569 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative assessment using General Health Questionnaire (GHQ‐28)
Number of subjects: 371
Study 15992569 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness Perception Questionnaire (IPQ)
Number of subjects: 371
Study 15992569 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Adjustment to Cancer Scale (MAC)
Number of subjects: 371
Study 15992569 — intervention group
Group type: EXPERIMENTAL
Intervention: Eysenck Personality Scales (EPS)
Number of subjects: 371
Study 12790216 — intervention group
Group type: COMPARATOR
Intervention: Morphine 0.4 mg mL(‐1)
Number of subjects: 90
Study 12790216 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 0.4 mg mL(‐1) + MgSO4 30 mg mL(‐1)
Number of subjects: 90
Study 12790216 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 0.4 mg mL(‐1) + ketamine 1 mg mL(‐1)
Number of subjects: 90